Lipocine Dividend

Dividend criteria checks 0/6

Lipocine does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.3%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$3.08
Dividend yield forecast in 3Yn/a

Recent dividend updates

No updates

Recent updates

Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%

Sep 26

Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Feb 22
Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?

Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Sep 14
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?

Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression

Jun 14

Lipocine competitor prevails in patent infringement lawsuit for Jatenzo

May 26

When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

May 11
When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?

Lipocine EPS beats by $0.01

May 06

Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Jan 26
Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?

Lipocine announces positive results from phase 2biopsy-confirmed NASH study

Jan 12

FDA Ok's Lipocine's testosterone replacement therapy, tentatively

Dec 09

Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Dec 04
Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?

Lipocine EPS misses by $0.01

Nov 10

Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection

Nov 06

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LPCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LPCN's dividend payments have been increasing.


Dividend Yield vs Market

Lipocine Dividend Yield vs Market
How does LPCN dividend yield compare to the market?
SegmentDividend Yield
Company (LPCN)n/a
Market Bottom 25% (US)1.5%
Market Top 25% (US)4.7%
Industry Average (Pharmaceuticals)2.3%
Analyst forecast in 3 Years (LPCN)n/a

Notable Dividend: Unable to evaluate LPCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LPCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LPCN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LPCN has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.